• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Continuous Glucose Monitoring for Type 2 Diabetes in Primary Care: 2021 Research Review

Article

Continuous glucose monitoring for type 2 diabetes patients is gaining exposure in the literature with positive evidence accumulating. Examples follow.

Numerous studies have shown continuous glucose monitoring (CGM) to be beneficial for patients with type 1 diabetes (T1D). Until recently, evidence for the use of CGM for patients with T2D has been lacking.

Studies and reviews published in 2021 are now addressing the use of CGM for patients with T2D, especially those in primary care. Scroll through the slides below for concise summaries of key findings.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024 / Image credit: ©Rasi/AdobeStock

New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024

Sydney Jennings
October 23rd 2024
Article

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

October Issue of Patient Care Online Supplement is Now Live

October Issue of Patient Care Online Supplement is Now Live

Sydney Jennings
October 14th 2024
Article

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

First-Ever CGM Cleared for 365-Day Use / image credit - CGM concept: ©yurii/stock.adobe.com

First-Ever CGM Cleared for 365-Day Use

Grace Halsey
September 20th 2024
Article

The only CGM system cleared for 1 year of use in type 1 and 2 diabetes is expected to be available in the fourth quarter of this year, the manufacturers said.

Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment

Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment

Sydney Jennings
September 11th 2024
Article

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

© 2024 MJH Life Sciences

All rights reserved.